Incyte Will First Seek Myelofibrosis, Rheumatoid Arthritis Indications For Lead JAK Compound

Oral Janus associated kinase inhibitor '424 may prove superior to currently approved anti-TNF agents and Roche’s IL-6 inhibitor Actemra for RA, Incyte CEO says.